Restricting Forum Shopping: McConnell Bill Takes Aim at Patent and Bankruptcy Venue Choices

Senate Minority Leader Mitch McConnell has initiated policy discourse with his recent legislative proposal that will likely place a heavy focus on the venue choices of patent owner litigations and bankrupt companies. This turn of events intensifies scrutiny on strategic forum shopping, a practice now potentially endangered by this bill. Certain patent owners and bankruptcy-bound…

Read More

USPTO Warns Attorneys of Risks and Ethical Guidelines in AI Usage

In a detailed briefing, the U.S. Patent and Trademark Office (USPTO) outlined potential risks for attorneys utilising artificial intelligence. Among these outlined concerns, the office emphasised the need for practicing legal professionals to ensure the accuracy of their filings and additionally stressed that humans must play a role in creations and discoveries. This briefing has…

Read More

Cannabis Market Expansion Challenges Trademark Protection Amid Federal Uncertainties

In 2018, the US saw a significant shift in legislation surrounding cannabis, as Congress passed the Agricultural Improvement Act, commonly referred to as the “2018 Farm Bill”. The Act led to the reclassification of hemp — described as Cannabis sativa L. and its derivatives exhibiting delta-9-tetrahydrocannabinol (THC) concentration levels not exceeding 0.3% on a dry…

Read More

Patent Case Appeal Stirs Debate on Court Appearances and Litigation Financing

A recent patent-case appeal case involves a defendant refusing to attend court in person, causing a stir in the legal community. A federal circuit panel signaled a general consensus, deeming it improbable the sanctions imposed by a district judge against a patent-infringement offender would be overturned. The plaintiff in question, Lori LaPray, refused to travel…

Read More

AI Advancements in Pharma: Accelerating Drug Discovery, Yet Challenging Patent Protection

In a fast-evolving pharma space, artificial intelligence (AI) has proven to be a two-pronged tool. The technology is aiding drug discovery at an accelerated pace but is also complicating patent acquisition, something that could deter billions in investments. One of the key issues is that AI’s capacity to generate ‘prior art’ or pre-existing evidence that…

Read More

Meta Transfers AI Patents to Research Lab, Encouraging Open-Source Innovation

In an interesting recent development, Meta Platforms Inc. has reportedly transferred a collection of patents related to Artificial Intelligence technology to a research laboratory. This move was confirmed by none other than Jeremiah Chan, the head of patents, licensing, and open source at Meta. Chan illuminated the rationale behind this decision, explaining, “Sharing these assets…

Read More

Dish Network’s $3.9 Million Patent Fees Award Under Federal Circuit Scrutiny

Controversy continues to surround the $3.9 million attorneys’ fees award granted to Dish Network LLC against patent-assertion entity, Realtime Adaptive Streaming LLC. A Federal Circuit oral argument held on Tuesday probed questions about a district judge’s justifications for such a substantial award. The three-judge panel at the US Court of Appeals for the Federal Circuit…

Read More

Nixon Peabody Bolsters IP Practice with Addition of Tim Maloney in Chicago

Nixon Peabody, one of the prominent global law firms, is expanding its Intellectual Property (IP) Practice in Chicago by adding Tim Maloney to their Partner, the firm reported on Tuesday. Maloney, with his extensive experience as a trial lawyer focusing on intellectual property enforcement and defense, will bring significant expertise to Nixon Peabody’s IP Practice….

Read More

Verizon Alleges Deceptive Asset Transfers by Traxcell Technologies in Legal Fee Evasion

Verizon Wireless has sought intervention from a Texas federal judge in a case it alleges involves Traxcell Technologies LLC engaging in deceptive asset-transfer practices to circumvent the payment of over $500,000 in legal fees. The legal fees were previously awarded to Verizon following an attorney misconduct incident during an extensive patent disagreement. The Cellco Partnership,…

Read More

Amarin Pharma Faces Antitrust Suit Over Vascepa Ingredient Monopolization

Teva Pharmaceuticals USA Inc. has enlisted Kirkland & Ellis in their legal battle against Amarin Pharma, an Irish based pharmaceutical firm. Teva’s antitrust suit accuses Amarin of dangerously monopolising the market for the principal ingredient in its cardiovascular health drug, Vascepa, thus thwarting competition from generic brands. The specific accusation is that the company has…

Read More

FDA Approves Merck’s Innovative Winrevair for Pulmonary Arterial Hypertension Treatment

Merck’s newly approved drug for Pulmonary Arterial Hypertension (PAH), known as Winrevair or sotatercept during its development phase, marks a significant step forward in treating this potentially life-threatening lung and heart disorder. Unlike the current roster of PAH treatments which primarily alleviate symptoms, Winrevair targets the underlying cause behind the malfunctioning signaling pathway that precipitates…

Read More